ALK and Alzheimer disease: Mutations of the oncogenes KRAS (25–40%), EGFR (10–15%), BRAF (2–4%), and HER2 (2%), and translocations of ALK (5–7%) and ROS1 (2%) are found predominantly in AD at frequencies indicated in brackets, most of which are targets for currently available or potential targeted therapies [5].